Treating Acute Leukemias
in Europe
Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases
Overview
This 3-hour virtual meeting will bring together leading experts to review the latest advances in adult acute lymphoblastic leukemia (ALL), including a preview of anticipated practice-changing data and key developments expected at ASH 2026. Through expert presentations, case-based discussions, and interactive faculty panels, participants will explore prognostic markers, frontline and relapsed/refractory treatment strategies, and the evolving roles of CAR T therapy, bispecific antibodies, and transplantation. The program is designed to translate emerging science into practical clinical insights that can enhance treatment decision-making and improve patient outcomes across Europe.
Date and Location
23 November 2026
Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty
Josep-Maria Ribera, MD, PhD
Catalan Institute of Oncology, Badalona, Spain
Nicolas Boissel, MD, PhD
Saint-Louis Hospital, Paris, France
Nicola Gökbuget, MD
Goethe University Frankfurt, Germany
|
Agenda |
23 November 2026
17.30 – 20.30 (CET)
| Time (CET) | Topic | Presenter |
| 17.30 – 17.35 | Welcome and Meeting Overview; Introduction to the Voting System | Elias Jabbour |
| 17.35 – 18.00 | Latest Achievements and Developments in ALL: Key Advances, Emerging Data, and What to Expect at ASH 2026 | Elias Jabbour |
| 18.00 – 18.20 | Review of Prognostic and Predictive Markers in ALL | Nicola Gökbuget |
| 18.20 – 18.45 | First-Line Treatment Best Practices in ALL: Optimizing Care Across Ph+, AYA, and Older Patients, Including Expected ASH 2026 Frontline Updates | Josep-Maria Ribera |
| 18.45 – 19.10 | Relapsed/Refractory (R/R) ALL: Treatment Strategies Across Ph−, and Ph+, and the Evolving Role of Transplantation in Europe, Including Expected ASH 2026 R/R Updates | Nicolas Boissel |
| 19.10 – 19.20 | Break | |
| 19.20 – 19.35 | Patient Case 1: ALL Case-Based Panel Discussion for First-Line Therapy | Lead: Josep-Maria Ribera; Panelists: All faculty |
| 19.35 – 19.50 | Patient Case 2: ALL Case-Based Panel Discussion for R/R ALL | Lead: Nicolas Boissel; Panelists: All faculty |
| 19.50 – 20.25 | Panel Discussion: Optimizing Treatment Pathways in Adult ALL | Moderator: Nicola Gökbuget; Elias Jabbour and all faculty |
| 20.25 – 20.30 | Session Close | Elias Jabbour |
